Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991296 | ...

Bright Health Group, Inc. (BHG) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Stephen Hagan - Investor Relations Director Mike Mikan - President and CEO Cathy Smith - Chief Administrative Officer and CFO Conference Call Participants Operator Ladies and gentlemen, welcome to the Bright Health Group First Quarter 2023 Earnings Call. My name is Kelly, and I will be coordinating your call today. I will now hand you over to Stephen Hagan, Investor Relations Director to begin. Steph ...

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group First Quarter 2023 – Earnings Presentation | | | May 9, 2023 | | Disclaimer 2 Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operation ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991296 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 8000 Norman Center Drive, Suite ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (State or o ...

Financial Data and Key Metrics Changes - For Q4 2022, revenue for continuing operations was $551 million, with a full year total of $2.4 billion [24] - The adjusted EBITDA loss for Q4 was $109 million, with a full year adjusted EBITDA loss of $233 million [26] - The full year net loss for continuing and discontinued operations was $1.36 billion, including approximately $500 million of non-cash charges [26] Business Line Data and Key Metrics Changes - The Consumer Care segment generated $364 million in revenue for Q4 and $1.8 billion for the full year [24] - Bright HealthCare revenue for Q4 was $394 million, totaling $1.7 billion for the full year [24] - Value-based care consumers in the Consumer Care segment increased to approximately 530,000 in Q4, with over 410,000 from Bright HealthCare [27] Market Data and Key Metrics Changes - The California Medicare Advantage market is a focus area, with expectations to grow from over 120,000 Medicare Advantage consumers to over 125,000 by year-end [14] - The medical cost ratio for Bright HealthCare was reported at 93.9% for the full year, with California operations achieving approximately 92% [25] Company Strategy and Development Direction - The company is transitioning away from the ACA marketplace insurance business, focusing on value-driven care and managing risk more effectively [15][41] - The strategic focus includes building strong relationships with payer partners and moving towards greater risk-sharing models over time [10][58] - The company aims for adjusted EBITDA profitability in both segments and at the enterprise level in 2023 [8][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continuing business's positioning for future growth, particularly in serving aging and underserved consumers [41] - The company is actively working on strengthening its capital position and addressing the liabilities from discontinued operations [22][42] - Management highlighted the importance of cash flow predictability and reduced volatility in the new business model [48] Other Important Information - The company has entered into a waiver and amendment with its bank group to reduce minimum liquidity requirements through April 30 [16] - The financial statements will include a going-concern qualification, emphasizing the need for additional capital to fund ongoing operations [22] Q&A Session Summary Question: Improvement in EBITDA from MA revenue growth - Management indicated that the primary driver for EBITDA improvement is the rate increase, with expectations for improved coding and risk adjustment factors contributing to growth [45][46] Question: Cash flow situation and needs by April - Management noted that the current cash position is about $150 million, with expectations to end 2023 with $200 million to $300 million in corporate cash [50][51] Question: Commercial contracting landscape - Management reported positive discussions with commercial plans regarding risk collars and contracts, with a focus on moving towards full risk contracts over time [58][59] Question: EBITDA bridge for Consumer Care - Management explained that the shift towards third-party payer contracts and improved performance from owned clinics are driving the expected EBITDA improvement [65] Question: Profitability expectations for ACO REACH members - Management expects comparable performance for ACO REACH members, with a projected loss ratio around 98% for 2023 [78]

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group Fourth Quarter 2022 – Earnings Presentation | | | March 1, 2023 | | Disclaimer 2 Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 BRIGHT HEALTH GROUP, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-4991 ...

Bright Health Group, Inc. (BHG) Q3 2022 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Stephen Hagan - Director, IR Mike Mikan - President & CEO Cathy Smith - CFO & CAO Conference Call Participants Nathan Rich - Goldman Sachs Joshua Raskin - Nephron Research Steven Valiquette - Barclays Lisa Gill - J.P. Morgan Chase Michael Hall - Morgan Stanley Kevin Fischbeck - Bank of America Gary Taylor - Cowen Operator Hello and welcome to today's Bright Health Group Third Quarter 2022 Earnin ...

| --- | --- | |-------------------------------------------------------------------|-------| | | | | | | | | | | Bright Health Group Third Quarter 2022 – Earnings Presentation | | | November 9, 2022 | | Disclaimer 2 Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements, and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results o ...